Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.

Adult Antibodies, Neutralizing / blood BNT162 Vaccine / administration & dosage COVID-19 / immunology ChAdOx1 nCoV-19 / administration & dosage Female France / epidemiology Hospitals, University Humans Immunologic Memory / immunology Incidence Male Memory B Cells / immunology Memory T Cells / immunology Middle Aged SARS-CoV-2 / immunology Spike Glycoprotein, Coronavirus / immunology Vaccination / statistics & numerical data

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
12 2021

Historique:

received: 19 07 2021

accepted: 10 10 2021

pubmed: 22 10 2021

medline: 11 1 2022

entrez: 21 10 2021

Statut: ppublish

Résumé

Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine

Identifiants

DOI: 10.1038/s41586-021-04120-y PMID: 34673755

pubmed: 34673755

doi: 10.1038/s41586-021-04120-y

pii: 10.1038/s41586-021-04120-y

doi:

Substances chimiques

Antibodies, Neutralizing 0

Spike Glycoprotein, Coronavirus 0

spike protein, SARS-CoV-2 0

ChAdOx1 nCoV-19 B5S3K2V0G8

BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

701-706

Investigateurs

Kahina Saker (K)

Christelle Compagnon (C)

Bouchra Mokdad (B)

Constance d'Aubarede (C)

Virginie Pitiot (V)

Vanessa Escuret (V)

Florence Morfin (F)

Mary-Anne Trabaud (MA)

Margaux Prieux (M)

Valérie Dubois (V)

Laurence Josset (L)

Soizic Daniel (S)

Informations de copyright

Références

Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092–2101 (2021).

doi: 10.1056/NEJMoa2104840

Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2202–2211 (2021).

doi: 10.1056/NEJMoa2105385

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

doi: 10.1056/NEJMoa2034577

Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime–boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979–1993 (2021).

doi: 10.1016/S0140-6736(20)32466-1

Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).

doi: 10.1016/S0140-6736(20)32661-1

Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime–boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856–869 (2021).

doi: 10.1016/S0140-6736(21)01694-9

Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime–boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir. Med. 9, 1255-1265 (2021).

doi: 10.1016/S2213-2600(21)00357-X

Legros, V. et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell. Mol. Immunol. 18, 318–327 (2021).

doi: 10.1038/s41423-020-00588-2

Gonzalez, C. et al. Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerg. Microbes Infect. 10, 1499–1502 (2021).

doi: 10.1080/22221751.2021.1945423

Sanz, I. et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front. Immunol. 10, 2458 (2019).

doi: 10.3389/fimmu.2019.02458

Lu, S. Heterologous prime–boost vaccination. Curr. Opin. Immunol. 21, 346–351 (2009).

doi: 10.1016/j.coi.2009.05.016

Jou, J., Harrington, K. J., Zocca, M.-B., Ehrnrooth, E. & Cohen, E. E. W. The changing landscape of therapeutic cancer vaccines—novel platforms and neoantigen identification. Clin. Cancer Res. 27, 689–703 (2021).

doi: 10.1158/1078-0432.CCR-20-0245

Levine, M. Z. et al. Heterologous prime–boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost. NPJ Vaccines 4, 22 (2019).

doi: 10.1038/s41541-019-0114-8

Spencer, A. J. et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat. Commun. 12, 2893 (2021).

doi: 10.1038/s41467-021-23173-1

Alizon, S. et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Euro Surveill. 26, 2100573 (2021).

doi: 10.2807/1560-7917.ES.2021.26.28.2100573

Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 27, 1530–1535 (2021).

doi: 10.1038/s41591-021-01464-w

Tenbusch, M. et al. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect. Dis. 21, 1212–1213 (2021).

doi: 10.1016/S1473-3099(21)00420-5

Groß, R. et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime–boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. Preprint at https://doi.org/10.1101/2021.05.30.21257971 (2021).

von Rhein, C. et al. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J. Virol. Methods 288, 114031 (2021).

doi: 10.1016/j.jviromet.2020.114031

Juraszek, J. et al. Stabilizing the closed SARS-CoV-2 spike trimer. Nat. Commun. 12, 244 (2021).

doi: 10.1038/s41467-020-20321-x

Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861–880 (2021).

doi: 10.1016/j.cell.2021.01.007

Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).

doi: 10.1126/scitranslmed.abf1555

Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021).

doi: 10.1038/s41586-021-03696-9

Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).

doi: 10.1056/NEJMoa1113425

Tomaras, G. D. et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl Acad. Sci. USA 110, 9019–9024 (2013).

doi: 10.1073/pnas.1301456110

Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).

doi: 10.1016/S0140-6736(21)00432-3

Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714 (2021).

Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 27, 1525–1529 (2021).

doi: 10.1038/s41591-021-01449-9

Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).

doi: 10.1038/s41591-020-0913-5

Broer, R., Boson, B., Spaan, W., Cosset, F.-L. & Corver, J. Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry. J. Virol. 80, 1302–1310 (2006).

doi: 10.1128/JVI.80.3.1302-1310.2006

Lavillette, D. et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79, 6023–6034 (2005).

doi: 10.1128/JVI.79.10.6023-6034.2005